Ray Dalio’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $13.8M | Buy |
171,923
+95,161
| +124% | +$7.85M | 0.06% | 210 |
|
|
2025
Q4 | $6.54M | Sell |
76,762
-103,545
| -57% | -$8.5M | 0.02% | 454 |
|
|
2025
Q3 | $14M | Sell |
180,307
-264,617
| -59% | -$20.7M | 0.05% | 261 |
|
|
2025
Q2 | $34.8M | Buy |
444,924
+382,402
| +612% | +$28.5M | 0.14% | 117 |
|
|
2025
Q1 | $4.53M | Sell |
62,522
-45,763
| -42% | -$3.28M | 0.02% | 372 |
|
|
2024
Q4 | $8.02M | Sell |
108,285
-57,166
| -35% | -$4M | 0.04% | 283 |
|
|
2024
Q3 | $10.9M | Sell |
165,451
-354,361
| -68% | -$25.7M | 0.06% | 252 |
|
|
2024
Q2 | $48M | Buy |
519,812
+34,145
| +7% | +$3.02M | 0.25% | 66 |
|
|
2024
Q1 | $46.4M | Sell |
485,667
-417,561
| -46% | -$35.1M | 0.23% | 79 |
|
|
2023
Q4 | $68.9M | Sell |
903,228
-152,368
| -14% | -$10.6M | 0.39% | 57 |
|
|
2023
Q3 | $73.1M | Buy |
1,055,596
+273,312
| +35% | +$22M | 0.44% | 47 |
|
|
2023
Q2 | $73.8M | Sell |
782,284
-160,942
| -17% | -$14M | 0.46% | 46 |
|
|
2023
Q1 | $78M | Buy |
943,226
+36,667
| +4% | +$2.88M | 0.48% | 45 |
|
|
2022
Q4 | $67.6M | Sell |
906,559
-224,153
| -20% | -$17.3M | 0.37% | 57 |
|
|
2022
Q3 | $93.4M | Buy |
1,130,712
+135,355
| +14% | +$13M | 0.47% | 43 |
|
|
2022
Q2 | $94.6M | Sell |
995,357
-139,899
| -12% | -$14.5M | 0.4% | 49 |
|
|
2022
Q1 | $134M | Buy |
1,135,256
+328,371
| +41% | +$36.8M | 0.54% | 28 |
|
|
2021
Q4 | $105M | Buy |
806,885
+117,220
| +17% | +$13.7M | 0.61% | 30 |
|
|
2021
Q3 | $78.1M | Sell |
689,665
-7,619
| -1% | -$870K | 0.43% | 44 |
|
|
2021
Q2 | $72.2M | Buy |
697,284
+307,385
| +79% | +$29M | 0.46% | 42 |
|
|
2021
Q1 | $32.6M | Buy |
389,899
+76,657
| +24% | +$6.48M | 0.29% | 72 |
|
|
2020
Q4 | $28.6M | Buy |
313,242
+169,585
| +118% | +$14.1M | 0.25% | 62 |
|
|
2020
Q3 | $11.5M | Buy |
+143,657
| New | +$11.2M | 0.14% | 74 |
|
|
2020
Q2 | – | Sell |
-7,386
| Closed | -$464K | – | 431 |
|
|
2020
Q1 | $464K | Buy |
+7,386
| New | +$533K | 0.01% | 292 |
|
|
2019
Q4 | – | Sell |
-28,743
| Closed | -$2.11M | – | 516 |
|
|
2019
Q3 | $2.11M | Buy |
28,743
+6,342
| +28% | +$446K | 0.02% | 194 |
|
|
2019
Q2 | $1.38M | Buy |
+22,401
| New | +$1.35M | 0.01% | 227 |
|
|
2018
Q4 | – | Sell |
-28,770
| Closed | -$1.67M | – | 489 |
|
|
2018
Q3 | $1.67M | Buy |
+28,770
| New | +$1.41M | 0.02% | 187 |
|
|
2018
Q1 | – | Sell |
-98,496
| Closed | -$3.7M | – | 473 |
|
|
2017
Q4 | $3.7M | Sell |
98,496
-260,745
| -73% | -$9.57M | 0.03% | 111 |
|
|
2017
Q3 | $13.1M | Buy |
359,241
+237,159
| +194% | +$9.05M | 0.09% | 51 |
|
|
2017
Q2 | $4.81M | Sell |
122,082
-14,163
| -10% | -$517K | 0.04% | 96 |
|
|
2017
Q1 | $4.27M | Buy |
+136,245
| New | +$4.27M | 0.05% | 106 |
|
|
2016
Q4 | – | Sell |
-135,195
| Closed | -$5.43M | – | 298 |
|
|
2016
Q3 | $5.43M | Buy |
135,195
+33,795
| +33% | +$1.27M | 0.05% | 114 |
|
|
2016
Q2 | $3.37M | Buy |
101,400
+45,000
| +80% | +$1.54M | 0.04% | 161 |
|
|
2016
Q1 | $1.66M | Buy |
+56,400
| New | +$1.56M | 0.02% | 200 |
|
|
2015
Q3 | – | Sell |
-191,688
| Closed | -$4.55M | – | 460 |
|
|
2015
Q2 | $4.55M | Buy |
+191,688
| New | +$4.33M | 0.04% | 121 |
|
|
2013
Q4 | – | Sell |
-154,170
| Closed | -$1.79M | – | 316 |
|
|
2013
Q3 | $1.79M | Buy |
+154,170
| New | +$1.8M | 0.02% | 171 |
|
Other funds holding EW
VCM
VPM
Ray Dalio's EW Position: Q1 2026 in Review
Ray Dalio increased its Edwards Lifesciences (EW) stake by 124% in Q1 2026, buying an estimated $7.85M and bringing the position to 171,923 shares worth $13.8M. The position accounts for 0.06% of the portfolio, ranked #210.
Ray Dalio first reported a position in EW in Q3 2013 and has held it in 36 quarters since. The position peaked at $134M in Q1 2022. 1,287 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Ray Dalio held 171,923 shares of Edwards Lifesciences worth $13.8M as of Q1 2026.
- Ray Dalio bought 95,161 Edwards Lifesciences shares in Q1 2026, an estimated $7.85M.
- Edwards Lifesciences made up 0.06% of Ray Dalio's portfolio in Q1 2026, its #210 holding.
- Ray Dalio first reported a position in Edwards Lifesciences in Q3 2013 and has held it in 36 quarters since.
- Ray Dalio's Edwards Lifesciences position peaked at $134M in Q1 2022.
- 1,287 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.